Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472232 | 0.93 | GAA (0.54) | KMT2AFKBP1ANPC1RAB9AMEN1 | |
| SCHEMBL2472263 | 0.91 | MEN1 (0.59) | KMT2AFKBP1AMEN1HSD11B1GAA | |
| SCHEMBL2472160 | 0.91 | FKBP1A (0.51) | KMT2AFKBP1AMEN1HSD11B1GAA | |
| SCHEMBL2469084 | 0.89 | KMT2A (0.61) | KMT2AFKBP1ANPC1MEN1GAA | |
| SCHEMBL2465751 | 0.87 | MEN1 (0.50) | KMT2AFKBP1AMEN1HSD11B1GAA | |
| SCHEMBL2471923 | 0.86 | TP53 (0.47) | KMT2AFKBP1AMEN1HSD11B1POLB | |
| SCHEMBL2465689 | 0.85 | ALDH1A1 (0.52) | KMT2AMEN1GAAPOLBMAPT | |
| SCHEMBL2468347 | 0.83 | ALDH1A1 (0.55) | KMT2AFKBP1ANPC1MEN1MAPT | |
| SCHEMBL2467872 | 0.83 | ALDH1A1 (0.49) | KMT2AMEN1HSD11B1MAPTALDH1A1 | |
| SCHEMBL2471026 | 0.83 | EPHX1 (0.50) | KMT2AMEN1POLBMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | KMT2A 957/4885FKBP1A 1791/4885NPC1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.